Reyvow
(Lasmiditan)ApprovedSmall molecule
Eli LillyLasmiditan is used to treat acute migraine headaches. It works by narrowing blood vessels around the brain and reducing substances in the body that can trigger headaches, nausea, sensitivity to light and sound, and other migraine symptoms.[2] Reyvow is currently approved and in use across 2 indications[4].[1]
Reyvow is one of 96 small molecule programs targeting Drug Dependence. It is currently in Approved.
2
Indications
31
Total Trials
0
Active Trials
95
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Competition
Competitive Landscape
63 competitors in Migraine Disorder
#DrugCompanyPhaseTrials
1Toradol
RocheApproved
Niacor
AbbVieApproved
Estrace
Novo NordiskApproved
Epidiolex
Jazz PharmaceuticalsApproved
Depakote
AbbVieApproved
Bayer Aspirin
BayerApproved
Revia
TevaApproved
Medrol
PfizerApproved
Vimpat
UCBApproved
Aleve
Jazz PharmaceuticalsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Migraine12 trials
Show 9 more trials
ART8 trials
Show 5 more trials
Driving2 trials
Oral1 trial
7 more indications
Impaired Renal Function1 trial
Hepatic Function1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Jan 31, 2020
REYVOW
NDA NDA211280
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Reyvow drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Lasmiditan. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Reyvow. U.S. Food & Drug Administration.
- [7]